The present application provides a compound of Formula (A), or a pharmaceutically acceptable salt thereof, wherein R.sup.1, L.sup.1, n, L.sup.2, m, L.sup.3, p, Y.sup.2, and Y.sup.3 are as described herein. Methods of using the compound of Formula (A) to prepare an antibody conjugate, and methods of using these conjugates for cellular imaging are also described.

##STR00001##

The present application provides a compound of Formula (A), or a pharmaceutically acceptable salt thereof, wherein R.sup.1, L.sup.1, n, L.sup.2, m, L.sup.3, p, Y.sup.2, and Y.sup.3 are as described herein. Methods of using the compound of Formula (A) to prepare an antibody conjugate, and methods of using these conjugates for cellular imaging are also described.

##STR00001##

The present disclosure relates to a gas hydrate inhibitor composition, comprising A) a compound according to formula (1) ##STR00001## wherein R1 is an alkyl group having from 1 to 5 carbon atoms; R2 is hydrogen or an alkyl group having from 1 to 5 carbon atoms; R3 is present or not as hydrogen and organic moieties having from 1 to 20 carbon atoms; R4 is selected from —(CH.sub.2).sub.t—, —[CH.sub.2—CHR.sup.6).sub.t]—, —(CH.sub.2—CHR.sup.6O).sub.u—(CH.sub.2).sub.t— and combinations thereof; R5 is an alkyl or alkenyl group having 4 to 22 carbon atoms; R6 is hydrogen or an alkyl group having from 1 to 4 carbon atoms; R7 is hydrogen or an alkyl group having from 1 to 4 carbon atoms; R8 is present or not as hydrogen or organic moieties having from 1 to 20 carbon atoms; t is 2, 3 or 4; u is an integer between 0 and 100; n is 0 or 1 m is 0 or 2 o is 0 or 2, p is 0 or 1 X.sup.− is an anion, and a synergistic cationic surfactant which is selected from quaternary benzyl ammonium salts having besides the benzyl group at least one C.sub.8-C.sub.18-alkyl group bound to the nitrogen atom.

The present disclosure relates to a gas hydrate inhibitor composition, comprising A) a compound according to formula (1) ##STR00001## wherein R1 is an alkyl group having from 1 to 5 carbon atoms; R2 is hydrogen or an alkyl group having from 1 to 5 carbon atoms; R3 is present or not as hydrogen and organic moieties having from 1 to 20 carbon atoms; R4 is selected from —(CH.sub.2).sub.t—, —[CH.sub.2—CHR.sup.6).sub.t]—, —(CH.sub.2—CHR.sup.6O).sub.u—(CH.sub.2).sub.t— and combinations thereof; R5 is an alkyl or alkenyl group having 4 to 22 carbon atoms; R6 is hydrogen or an alkyl group having from 1 to 4 carbon atoms; R7 is hydrogen or an alkyl group having from 1 to 4 carbon atoms; R8 is present or not as hydrogen or organic moieties having from 1 to 20 carbon atoms; t is 2, 3 or 4; u is an integer between 0 and 100; n is 0 or 1 m is 0 or 2 o is 0 or 2, p is 0 or 1 X.sup.− is an anion, and a synergistic cationic surfactant which is selected from quaternary benzyl ammonium salts having besides the benzyl group at least one C.sub.8-C.sub.18-alkyl group bound to the nitrogen atom.

Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.

Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Disclosed herein are methods of preparing N.sup.6-((2-azidoethoxy)carbonyl)lysine, N.sup.6-((2-azidoethoxy)carbonyl)-L-lysine, and N.sup.6-((2-azidoethoxy)carbonyl)-D-lysine. Also disclosed herein are the compounds tert-butyl N.sup.2-(tert-butoxycarbonyl)-N.sup.6-((2-chloroethoxy)carbonyl)-L-lysinate and tert-butyl N.sup.6-((2-azidoethoxy)carbonyl)-N.sup.2-(tert-butoxycarbonyl)-L-lysinate, and uses thereof.

Disclosed herein are methods of preparing N.sup.6-((2-azidoethoxy)carbonyl)lysine, N.sup.6-((2-azidoethoxy)carbonyl)-L-lysine, and N.sup.6-((2-azidoethoxy)carbonyl)-D-lysine. Also disclosed herein are the compounds tert-butyl N.sup.2-(tert-butoxycarbonyl)-N.sup.6-((2-chloroethoxy)carbonyl)-L-lysinate and tert-butyl N.sup.6-((2-azidoethoxy)carbonyl)-N.sup.2-(tert-butoxycarbonyl)-L-lysinate, and uses thereof.